Ekso Bionics (NASDAQ:EKSO) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The brokerage presently has a $2.25 target price on the stock. Zacks Investment Research‘s price target would suggest a potential upside of 20.97% from the company’s current price.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, ValuEngine downgraded Ekso Bionics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 2nd.
Ekso Bionics (NASDAQ:EKSO) last announced its quarterly earnings data on Wednesday, November 7th. The company reported ($0.11) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.02). Ekso Bionics had a negative return on equity of 257.70% and a negative net margin of 303.58%. The company had revenue of $2.55 million for the quarter, compared to analyst estimates of $2.86 million. On average, sell-side analysts predict that Ekso Bionics will post -0.45 earnings per share for the current fiscal year.
A number of hedge funds have recently bought and sold shares of EKSO. Bristol Advisors LLC purchased a new stake in Ekso Bionics during the third quarter worth approximately $107,000. EAM Investors LLC purchased a new stake in Ekso Bionics during the third quarter worth approximately $687,000. Citadel Advisors LLC lifted its stake in Ekso Bionics by 136.9% during the third quarter. Citadel Advisors LLC now owns 45,027 shares of the company’s stock worth $105,000 after purchasing an additional 26,017 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Ekso Bionics by 6.3% during the third quarter. Vanguard Group Inc. now owns 1,745,819 shares of the company’s stock worth $4,085,000 after purchasing an additional 103,277 shares during the last quarter. Hedge funds and other institutional investors own 38.40% of the company’s stock.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Recommended Story: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.